An observational study in Non-Small Cell Lung Cancer, sponsored by Biodesix, Inc.. Active, not recruiting at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Biodesix, Inc. · Observational
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
The primary purpose of this observational study is to assess the physician's clinical practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR mutational status. This study will also attempt to further validate that VeriStrat test results stratify subjects by clinical outcomes in the real world, uncontrolled clinical setting while exploring whether certain therapeutic approaches may yield opportunities for further study.
Predictive tests that aid physician therapeutic decision making are critical for optimizing subject outcomes while minimizing toxicity and associated treatment costs. This study will provide data for the validation of immunotherapy tests currently being developed. Immunotherapy mechanisms are dependent upon the interactions between the tumor, tumor microenvironment, and the patient immune system. As such, a successful predictive test will reflect the complex interplay between tumor and host. The multivariate tests from Biodesix have the advantage of being able to assess this complex biology.
The information gained from this research will not only guide the adoption of the VeriStrat test and inform medical decision making, including treatment choice, but will allow the validation of additional mass-spectrometry-based proteomic tests.
Any Subject with Non-Small Cell Lung Cancer (NSCLC) at all stages with any histology.
Exclusion Criteria:
1. Subject's ability to understand the requirements of the protocol or to provide informed consent is impaired or subject is unwilling to comply with the protocol requirements.
Physician Treatment Patterns Description
Physician Treatment patterns Description: To describe physician treatment patterns pre and post-veriStrat testing. Describe the impact of the VeriStrat test results on treatment decisions, including but not limited to: percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat good and those classified as VeriStrat Poor. Change in percentage of patients receiving systemic therapy or supportive therapies only.
Time frame: 3 years
Immunotherapy Stratification by Overall Survival
To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by overall survival.
Time frame: 3 years
Immunotherapy Stratification by Progression-Free Survival
To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by progression-free survival.
Time frame: 3 years
VeriStrat Poor vs. Good Outcomes
To compare progression free survival (PFS) and overall survival (OS) outcomes between those classified as VeriStrat-Poor and VeriStrat-Good.
Time frame: 3 years
Platinum-based therapy outcomes in VeriStrat Poor vs. Good subjects.
To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with platinum-based therapy.
Time frame: 3 years
Immunotherapy outcomes in VeriStrat Poor vs. Good subjects.
To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with immunotherapy.
Time frame: 3 years
Single agent chemotherapy outcomes in VeriStrat Poor vs. Good Subjects
To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with single agent chemotherapy.
Time frame: 3 years
VeriStrat label changes over time.
To compare the longitudinal changes in VeriStrat classification over the course of the study
Time frame: 3 years
Determination of Immunotherapy tests ability to stratify subjects based on treatment.
To determine whether immunotherapy test(s) stratify subjects treated with chemotherapy or targeted therapies by outcome.
Time frame: 3 years
Correlation between the VeriStrat test and Immunotherapy tests.
To observe the correlation between VeriStrat classification and immunotherapy test(s) classification at baseline and longitudinally.
Time frame: 3 years
Longitudinal changes in Immunotherapy tests.
To describe the longitudinal changes in immunotherapy test classification over the course of the study.
Time frame: 3 years
Stratification of Immunotherapy Test(s)
To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by other clinically meaningful factors or endpoints.
Time frame: 3 years
Changes in GeneStrat
To observe changes in GeneStrat status across lines of therapy.
Time frame: 3 years
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Biodesix, Inc.